Abstract
Systemic administration of cholecystokinin (CCK) fragments produces anxiogenic effects. The dorsal periaqueductal gray (dPAG) has been related to anxiety and panic reactions. The objective of this study was to investigate a possible anxiogenic effect of CCK-8 microinjected into the dPAG. At 10 min after the last microinjection (0.5 μl) into the dPAG male Wistar rats (N=7–17) were tested in the elevated plus-maze, an animal model of anxiety. The following treatments were tested alone or in combination: sulfated CCK-8 (CCK-8s, 0.5–1 μg), PD 135,158 (N-methyl-D-glucamine, 0.1 μg), a CCK-2 receptor antagonist, lorglumide (0.1–0.3 μg), a CCK-1 receptor antagonist. In addition, Fos immunohistochemistry was performed in rats (n=3–4) treated with CCK-8s (1 μg) alone or in combination with PD 135,158 (0.1 μg). CCK-8s produced anxiogenic-like effect, decreasing the percentage of time spent in open arm (saline=30.3±6.6, CCK 0.5 μg=15.2±1.8; CCK 1 μg=14.6±2.1). This effect was prevented by pretreatment with PD 135,158, but not by lorglumide. CCK-8s injected into the dPAG induced Fos immunoreactivity in several brain areas related to defensive behavior, including the PAG, median, and dorsal raphe nuclei, superior colliculus, lateral septal nuclei, medial hypothalamus, and medial amygdala. This effect was also prevented by pretreatment with PD 135,158. These results suggest that CCK-8s, acting on CCK-2 receptors, may modulate anxiety reactions in the dPAG.
Similar content being viewed by others
INTRODUCTION
The midbrain dorsal periaqueductal gray (dPAG) matter is a key structure in the control of defensive behaviors (Behbehani, 1995). Several neurotransmitters have been shown to modulate neuronal activity in this region. For example, injection into the dPAG of drugs that facilitate GABAergic or serotonergic neurotransmission attenuates the aversive consequences of dPAG electrical stimulation and produces anxiolytic-like effects in the elevated plus-maze (EPM, Russo et al, 1993; Lovick, 2000). Similar effects were produced by glutamate antagonists (Guimarães et al, 1991).
Neuropeptides may also modulate defensive responses in the PAG (Behbehani, 1995). Cholecystokinin (CCK) is one of the most widespread peptide system in the brain. It is involved in many brain physiological or pathological conditions, including anxiety, panic, and depression (Guimarães et al, 1992; Hernandez-Gomez et al, 2002; Bradwejn et al, 1992, 1994; Rehfeld, 2000). CCK-immunoreactive fibers and a high concentration of CCK exist in the PAG (De Belleroche et al, 1990; Liu et al, 1994). Aversive stimuli such as restraint, social isolation, or exposure to the smell of a predator increase CCK levels and/or expression in the PAG and limbic regions such as the amygdala and hippocampus (Del Bel and Guimarães, 1997; Pavlasevic et al, 1993; Rosen et al, 1992). Systemic injection of CCK agonists or anta-gonists produces anxiogenic or anxiolytic effects, respectively (Griebel et al, 1997, Hernandez-Gomez et al, 2002). These effects may involve the dPAG since systemic administration of anxiogenic compounds, including the CCK analogue BOC-CCK4, induces Fos immunoreactivity in the dPAG (Singewald and Sharp, 2000). Moreover, intra-dPAG injection of CCK-8s was reported to be anxiogenic in the EPM (Guimarães et al, 1992). The objective of the present work was to investigate the anxiogenic effects of CCK in the dPAG. We tested the hypothesis that these effects are mediated by CCK-2 receptors. Moreover, we used the expression of the immediate-early gene Fos as a marker of neuron functional activity (Morgan and Curran, 1995) to detect brain areas stimulated by CCK-8s injection into the dPAG.
MATERIALS AND METHODS
Subjects
Male Wistar rats (200–250 g) were housed in pairs with free access to food and water in a temperature controlled room (23±1°C) with a 12 h light, 12 h dark cycle (lights on at 0600). The experiments were carried out according to the Brazilian Society of Neuroscience and Behavior guidelines for care and use of Laboratory animals, and all efforts were made to minimize animal suffering.
Elevated plus-maze
The wood plus-shaped maze consisted of two open and two enclosed arms of equal length and width (50 × 10 cm). The enclosed arms had 40 cm high wooden walls while a 1-cm high edge made of Plexiglas surrounded the open arms to prevent falls.
The experiment was carried out in a sound attenuated, temperature-controlled (23±1°C) room. The environment was illuminated by two 40 W fluorescent lights placed 1.3 m away from the EPM.
Drugs
All drugs were dissolved in sterile isotonic saline. The doses of sulfated CCK octapeptide (CCK-8s, RBI, USA) were chosen based on previous work by our group (Guimarães et al, 1992). The doses employed for N-methyl-D-glucamine (PD 135,158, RBI, USA) and lorglumide (RBI, USA), potent and selective CCK-2 and CCK-1 receptor antagonists, respectively (Herranz, 2003), were based on the literature (Costall et al, 1991, Griebel et al, 1997).
Surgery
Rats were anesthetized with 2.5%. 2,2,2,-tribromoethanol (10 ml/kg, i.p.) and fixed in a stereotaxic frame to implant a stainless-steel guide cannula (0.7 mm, OD) into the dPAG (coordinates: AP: interaural 1.2 mm, lateral: 1.9 mm at an angle of 16° with the sagital plane). The guide cannula was introduced until its tip was 4.1 mm below the surface of the skull. The cannula was attached to the bone with stainless-steel screws and acrylic cement. An obturator inside the guide cannulae prevented obstruction.
Behavioral Studies
Intracerebral injections were performed with a thin dental needle (0.3 mm, OD) introduced through the guide cannula until its tip was 1 mm below the cannula end. A volume of 0.5 μl was injected during 30 s using an infusion pump (KdScientific). The movement of an air bubble inside the PE 10 polyethylene tubing connecting the pump with the dental needle confirmed drug flow. At 10 min after the last microinjection the rat was placed in the centre of the plus-maze facing an enclosed arm. The session was videotaped and analyzed later with the help of Ethovision (Version 1.9, Noldus, Netherlands) software. The program detects the position of the animal in the maze and calculates the number of entries and time spent in open and enclosed arms. For these calculations a 6-cm large ‘exclusion’ zone was added between the center of the maze and each arm so that most of the animal's body should be in the open or enclosed arm to an entry to be registered. Each session lasted for 5 min and after each trial the maze was cleaned with an alcohol solution.
The experiments took place 7 days after the surgery. Three experiments were performed.
Experiment 1: Animals received intra-dPAG injection of saline (n=9), CCK-8s 0.5 μg (n=11), or 1 μg (n=12), and were tested in the EPM 10 min later.
Experiment 2: The animals received a first microinjection into the dPAG of either saline (n=11–12) or PD 135,158 (0.1 μg, n=11–14) followed, 5 min later, by a second microinjection of saline or CCK-8s 1 μg.
Experiment 3: It was similar to experiment 3, except that the animals were pretreated with saline (n=14–17) or lorglumide (0.1 or 0.3 μg, n=7–14) before saline or CCK-8s administration.
Histological Control
After the behavioral tests the animals were killed under deep anesthesia and their brains perfused through the left ventricle of the heart with isotonic saline followed by 10% formalin solution. After that 0.2 μl of Fast green (1%) was injected through the guide cannula and the brains were removed. Following a minimum period of 3 days immersed in a 10% formalin solution, frozen sections of 50 μm were obtained in a cryostat (Cryocut, 1800). The injection sites were localized in diagrams from the Paxinos and Watson's (1987) rat brain atlas. No distinction was made between dorsomedial and dorsolateral PAG. Animals receiving microinjections outside the dPAG were excluded from analysis. Since most of these animals received their microinjection into the superior colliculus, they were compared in a separated analysis.
Fos Immunohistochemistry
Two experiments were performed. In experiment 1 animals received microinjection into the dPAG of saline (0.5 μl, n=4), CCK-8s (1 μg, n=4) or were left undisturbed in their home cages (naive, n=3). In the second experiment animals (n=2–4/group) received a first microinjection of saline (0.5 μl) or PD 135,158 (0.1 μg) followed, 5 min later, by a second microinjection of saline or CCK-8s (1 μg). At 2 h after the last injection the animals were anesthetized with an overdose of urethane and perfused transcardially with saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH=7.4). Brains were removed and postfixed over 2 h in paraformaldehyde and stored for at least 48 h in 30% sucrose for cryoprotection. Transverse sections (40 μm) were obtained in a cryostat and processed for Fos immunohistochemistry (Silveira et al, 1994). Tissue sections were washed and incubated overnight at room temperature with rabbit IgG (1/10.000 into PBS, sc-52, Santa Cruz), which was raised against an amino-acid sequence of the N-terminal region of the peptide and specifically recognizes Fos. Sections were then processed by the avidin–biotin immunoperoxidase method (Vectastain ABC kit, Vector Lab, Burlingame, CA, USA). Fos immunoreactivity (FIr) was revealed by the addition of the chromogen diaminobenzidin (Sigma) and visualized as a brown reaction product inside neuronal nuclei.
The number of Fos-positive nuclei was counted from a fixed area in regions selected from previous studies (De Oliveira et al, 2000, Lino-de-Oliveira et al, 2001) using a computerized image analysis system (Image-Pro Plus). For bilateral structures the mean value between each side was analyzed. The system was calibrated to ignore background staining. Darker objects with areas between 10 and 80 μm2 were identified as Fos-positive neurons as described by Lino-de-Oliveira et al (2001). The analyzed regions and their respective areas were as follows: frontal cortex (AP: 0.70 mm from bregma, Paxinos and Watson, 1987, area: 0.3 × 106 μm2), cingulate cortex (AP: 0.70 mm, area: 0.3 × 106 μm2), basolateral amygdala (BlAmyg, AP: −2.80 mm, area: 0.28 × 106 μm2), medial amygdala (MeAmyg, AP: −2.30 mm, area: 0.28 × 106 μm2), central nucleus of the amygdala (CeAmyg, AP: −2.56 mm, area: 0.28 × 106 μm2), lateral division of the bed nucleus of the stria terminalis, ventral part (BNSTv, AP: −0.26 mm, area: 0.14 × 106 μm2), medial division of the bed nucleus of the stria terminalis (BNSTm, AP: −0.26 mm, area: 0.25 × 106 μm2), lateral septal nucleus, dorsal, (LSd, AP: 0.20 mm, area: 0.25 × 106 μm2), intermediate (LSi, AP: 0.20 mm, area: 0.3 × 106 μm2) and ventral (LSv, AP: 0.20 mm, area: 0.3 × 106 μm2) parts, CA1 (AP: −3.14 to −3.30 mm, area: 0.20 × 106 mm2), CA2 (AP: −3.14 to −3.30 mm, area: 0.16 × 106 mm2), CA3 (AP: −3.14 to −3.30 mm, area: 0.20 × 106 mm2), anterior hypothalamic area (AntH, AP: −1.80 mm, area: 0.28 × 106 mm2), dorsomedial hypothalamic nucleus (DmH, AP: −3.14 mm, area: 0.30 × 106 mm2), lateral hypothalamus (LH, AP: −1.80 mm, area: 0.28 × 106 mm2), paraventricular nucleus of the hypothalamus, magnocellular (PVNm, AP: −1.80 mm, area: 0.43 × 106 μm2) and parvocellular (PVNp, AP: −1.80 mm, area: 0.12 × 106 μm2) parts, paraventricular nucleus of the thalamus (PVT, AP: −1.80 mm, area: .0.2 × 106 μm2), dorsolateral periaqueductal gray (dlPAG, AP: −6.80 to −7.30 mm, area: 0.3 × 106 μm2), lateral periaqueductal gray (lPAG, AP: −6.80 to −7.30 mm, area: 0.3 × 106 μm2), dorsomedial periaqueductal gray (dmPAG, AP: −6.80 to −7.30 mm, area: 0.3 × 106 μm2), median raphe nucleus (MRN, AP: −7.80 mm, area: 0.3 × 106 μm2), dorsal raphe nucleus (DRN, AP: −7.30 mm, area: 0.3 × 106 μm2) and superior colliculus (SC, AP: −6.80 to −7.30 mm, area: 0.3 × 106 μm2).The results are expressed as neuron density (number of positive cells in 0.1 mm2).
Statistical Analysis
The percentages of open arm entries (100 × open/total entries) and of time spent on the open arms (100 × open/open+enclosed) were calculated for each rat. The behavioral and Fos data were analyzed by t-test or one-way analysis of variance (ANOVA) followed by the Duncan test for multiple comparisons.
RESULTS
Behavioral Experiments
A diagram showing representative injection sites can be seen in Figure 1.
Experiment 1: CCK-8s decreased the percentage of time spent in open arms (F(2,29)=5.51, p<0.05, Figure 2). No effect was found in the number of enclosed arm entries (F(2,29)=0.65, NS) or percentage of entries onto open arms (F(2.29)=2.01, NS). Animals that received saline or CCK-8s 1 μg into the superior colliculus did not differ in any parameter (p>0.05, Figure 3).
Experiment 2: CCK-8s caused a significant decrease in percentage of time spent in open arms (F(3,48)=3.48, p<0.05, Duncan, p<0.05, Figure 4). This effect was prevented by pretreatment with PD 135,158 (Duncan, p>0.05). No significant difference was found in the number of enclosed arm entries (F(3,48)=0.96, NS) or percentage of open arm entries (F(3,48)=2.29, NS).
Experiment 3: CCK-8s decreased the percentage of time spent in open arm (F(5,71)=2.94, p=0.018, Duncan, p<0.05, Figure 5). This effect was not prevented by pretreatment with any dose of lorglumide (Duncan, p<0.05). No difference was found in the number of enclosed arm entries (F(5,71)=0.98, NS) or percentage of open arm entries (F(5,71)=1.08, NS).
Fos Immunohistochemistry
Experiment 1: Results can be seen in Table 1 and in Figure 6. CCK-8s induced a significant increase in FIr cells, as compared to saline and naive animals, in the MeAmyg (F(2,8)=16.4, p<0.005, Duncan, p<0.05, Table 1), LSd (F(2,8)=11.8, p<0.01, Duncan, p<0.05), LSv (F(2,8)=22.2, p<0.001, Duncan, p<0.05), PVNm (F(2,8)=5.11, p<0.05, Duncan, p<0.05), dlPAG (F(2,8)=15.7, p<0.01, Duncan, p<0.05), dmPAG (F(2,8)=6.4, p<0.05, Duncan, p<0.05), lPAG (F(2,8)=140.1, p<0.001, Duncan, p<0.05), DRN (F(2,8)=279.8, p<0.001, Duncan, p<0.01), MRN (F(2,8)=17.4, p<0.001, Duncan, p<0.05), and superior colliculus (F(2,8)=21.5, p<0.05, Duncan, p<0.05). In addition, significant differences between CCK-8s and naive groups were found in the frontal cortex (F(2,8)=8.0, p<0.05, Duncan, p<0.05), cingulated cortex (F(2,8)=5.6, p<0.05, Duncan, p<0.05), piriform cortex (F(2,8)=4.1, p<0.05, Duncan, p<0.05), blAmyg (F(2,8)=4.9, p<0.05, Duncan, p<0.05), CA1 (F(2,8)=14.3, p<0.005, Duncan, p<0.05), LSi (F(2,8)=10.0, p<0.01, Duncan, p<0.05), AntH (F(2,8)=8.4, p<0.05, Duncan, p<0.05), DmH (F(2,8)=8.35, p<0.05, Duncan, p<0.05), LH (F(2,8)=14.2, p<0.05, Duncan, p<0.05), PVNp (F(2,8)=5.5, p<0.05, Duncan, p<0.05), and PVT (F(2,8)=3.96, p<0.05, Duncan, p<0.05). In the piriform cortex, CA1, LSi, AntH, and LH the saline group was also different from naive animals (Duncan, p<0.05).
Experiment 2: Results are in Table 2. Rats treated with saline–CCK-8s had greater FIr cells, as compared to saline–saline and PD 135,158 treated animals, in the LH (F(3,8)=2.80, p=0.10, Duncan, p<0.05), PVT (F(3,8)=7.28, p<0.05, Duncan, p<0.05), dlPAG (F(3,8)=9.80, p<0.01, Duncan, p<0.05), SC (F(3,8)=11.9, p<0.01, Duncan, p<0.05), and DRN (F(3,8)=5.09, p<0.05, Duncan, p<0.05). Significant differences, as compared to saline–saline or PD 135,158 groups only, were found after saline–CCK-8s injection in, respectively, the lPAG (F(3,8)=3.6, p=0.06, Duncan, p<0.05) and MRN (F(3,8)=5.53, p<0.05, Duncan, p<0.05) or the BNSTm (F(3,8)=2.90, p=0.10, Duncan, p<0.05), LSd (F(3,8)=3.99, p=0.052, Duncan, p<0.05), and PVNp (F(3,8)=4.99, p<0.05, Duncan, p<0.05).
DISCUSSION
The EPM is a widely employed animal model of anxiety (File, 1992). Rodents usually avoid the open arms of this apparatus, most likely because they cannot engage in thigmotaxic behavior (Treit et al, 1993). CCK-8s decreased the percentage of time spent in the open arms, without changing the number of enclosed arm entries. The results suggest an anxiogenic effect (File, 1992) and are similar to those previously described by Guimarães et al (1992). Strengthening the role of the dPAG in this result, injections of CCK-8s into the superior colliculus had no effect.
The two doses of CCK-8s employed had similar effects, suggesting that a maximum effect in the dPAG was reached. This neuropeptide acts as a full agonist at both CCK-receptor subtypes (Fink et al, 1998). The anxiogenic effect of CCK-8s was completely prevented by pretreatment with PD 135,158, a CCK-2 receptor antagonist. Similar effects have been reported after i.c.v. administration of CCK-8s (Hernandez-Gomez et al, 2002). CCK-2 receptors are abundantly expressed in the brain and are present in the PAG (Mercer et al, 1996). Pharmacological studies suggest that they modulate anxiety reactions (Rehfeld, 2000). For example, CCK-4, a CCK-2 full agonist, induces panic symptoms in humans and anxiety-like behavior in rodents (Rehfeld, 2000).
Lorglumide pretreatment did not prevent the anxiogenic effect of CCK-8s. This drug is a selective and potent CCK-1 receptor antagonist (Herranz, 2003). The doses used were similar or higher than the one used with PD 135,158. However, pharmacological studies using systemic or i.c.v. administration of these compounds show that the active doses to antagonize CCK-1 or CCK-2 receptors, respectively, are similar (Felicio et al, 2001; Suh et al, 1995). Also, a lower dose of lorglumide was able to prevent CCK-1-mediated effect of a CCK agonist on tail flick responses after i.c.v. administration (Suh et al, 1996). Therefore, CCK-1 receptors are probably not involved in the anxiogenic effect of intra-dPAG administration of CCK-8s.
PD 135,158 administered alone had no effect in the EPM. This suggests that CCK-2-mediated neurotransmission in the dPAG does not play a significant role on anxiety induced by EPM exposure. This does not exclude the involvement of these receptors in anxiety modulation under more stressful conditions. For example, CCK-2 antagonism was able to decrease the anxiogenic effect of a cat exposure in rats tested in the EPM (Adamec et al, 1997). This could be related to the increased brain expression of CCK (Del Bel and Guimarães, 1997; Pavlasevic et al, 1993; Rosen et al, 1992) and CCK-2 mRNA (Wang et al, 2003) found after exposure to stressful conditions. It was proposed that, under these conditions, CCK could sensitize the PAG, facilitating depolarization of PAG neurons by glutamate excitatory inputs (Behbehani, 1995). Administration of CCK-8s into the dPAG induced Fos expression in several brain regions related to defensive behaviors (for a review, see Sewards and Sewards, 2002). However, the significant differences between saline-treated and naive animals showed that the injection procedure was also able to activate several of these regions. More consistent effects were found in midbrain structures such as the PAG itself, raphe nuclei, and superior colliculus, and in the lateral septal nuclei, medial amygdala, medial hypothalamus, paraventricular hypothalamus, and the paraventricular thalamic nucleus. All these areas are connected, directly or indirectly, to the dPAG (Shipley et al, 1991; Beitz, 1995). They are proposed to be part of a fear and power-dominance neural representation system that is activated by several threatening or stressful stimuli (Silveira et al, 1994; Canteras and Goto, 1999; Lino-de-Oliveira et al, 2001; Dilenberg and McGregor, 2001; Sewards and Sewards, 2002). In addition, the paraventricular thalamic nucleus has recently been implicated in the regulation of hypothalamic–pituitary–adrenal function through a CCK-mediated pathway recruited by chronic stress (Bhatnagar et al, 2000).
Similar to the behavioral data, pretreatment with PD 135,158 prevented the effect of CCK-8s on Fos expression. This reinforces the role of CCK-2 receptors on the effects induced by CCK-8s administration into the dPAG.
In conclusion, our data indicate that CCK-8s, acting on CCK-2 receptors, can modulate anxiety-like behaviors in the dPAG.
References
Adamec RE, Shallow T, Budgell J (1997). Blockade of CCK(B), but not CCK(A), receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: implications for anxiety associated with posttraumatic stress disorder. Behav Neurosci 111: 435–449.
Behbehani MM (1995). Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46: 575–605.
Beitz AJ (1995). Periaqueductal gray. In: Paxinos G (ed). The Rat Nervous System 2nd edn Academic Press: San Diego. pp 173–182.
Bhatnagar S, Viau V, Chu A, Soriano L, Meijer OC, Dallman MF (2000). A cholecystokinin-mediated pathway to the paraventricular thalamus is recruited in chronically stressed rats and regulates hypothalamic–pituitary–adrenal function. J Neurosci 20: 5564–5573.
Bradwejn J, Koszycki D, Cöuetoux Du Tertre A, Bourin M, Palmour R, Ervin F (1992). The cholecystokinin hypothesis of panic and anxiety disorders: a review. J Psychopharmacol 6: 345–351.
Bradwejn J, Koszycki D, Cöuetoux Du Tertre A, Van Megen H, Den Boer J, Westenberg H (1994). The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51: 486–493.
Canteras NS, Goto M (1999). Fos-like immunoreactivity in the periaqueductal gray of rats exposed to a natural predator. NeuroReport 10: 413–418.
Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991). Anxiolytic effects of CCKB antagonists. Neuropeptides 19(Suppl): 65–73.
De Belleroche J, Bandopadhyay R, King A, Malcolm ADBK, Premi BP, Rashid A (1990). Regional distribution of cholecystokinin messenger RNA in rat brain during development: quantification and correlation with cholecystokinin immunoreactivity. Neuropeptides 15: 201–212.
De Oliveira RW, Del Bel EA, Guimarães FS (2000). Behavioural and c-fos expression changes induced by nitric oxide donors microinjected into the dorsal periaqueductal gray. Brain Res Bull 51: 457–464.
Del Bel EA, Guimarães FS (1997). Social isolation increases cholecystokinin mRNA expression in the central nervous system of rats. NeuroReport 8: 3597–3600.
Dilenberg RA, McGregor IS (2001). Defensive behavior in rats towards predatory odors: a review. Neurosci Biobehav Rev 25: 597–609.
Felicio LF, Mazzini BK, Cacheiro RG, Cruz TN, Florio JC, Nasello AG (2001). Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitise a morphine-induced excitatory response. Peptides 22: 1299–1304.
File SE (1992). Behavioural detection of anxiolytic action. In: Elliott JM, Heal DJ, Marsden CA (eds). Experimental Approaches to Anxiety and Depression. John Wiley & Sons: New York. pp 25–44.
Fink H, Rex A, Voits M, Voigt JP (1998). Major biological actions of CCK—a critical evaluation of research findings. Exp Brain Res 123: 77–83.
Griebel G, Perrault G, Sanger DJ (1997). CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviors. Behav Pharmacol 8: 549–560.
Guimarães FS, Carobrez AP, De Aguiar JC, Graeff FG (1991). Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 103: 91–94.
Guimarães FS, Russo AS, De Aguiar JC, Ballejo G, Graeff FG (1992). Anxiogenic-like effect of CCK-8 micro-injected into the dorsal periaqueductal grey of rats in the elevated plus maze. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL (eds). Multiple Cholecystokinin Receptors in the CNS. Oxford Science Publication: Oxford. pp 149–154.
Hernandez-Gomez AM, Aguilar-Roblero R, Pérez de La Mora M (2002). Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Amino Acids 23: 283–290.
Herranz R (2003). Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23: 559–605.
Lino-de-Oliveira C, Sales AJ, Del Bel EA, Silveira MCL, Guimarães FS (2001). Effects of acute and chronic fluoxetine treatments on restraint stress-induced Fos expression. Brain Res Bull 55: 747–754.
Liu H, Chandler S, Beitz AJ, Shipley MT, Behbehani MM (1994). Characterization of the effect of cholecystokinin (CCK) on neurons in the periaqueductal gray of the rat: immunocytochemical and in vivo and in vitro electrophysiological studies. Brain Res 642: 83–94.
Lovick TA (2000). Panic disorder—a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter? Neuroscientist 6: 48–59.
Mercer LD, Beart PM, Horne MK, Finkelstein DJ, Carrive P, Paxinos G (1996). On the distribution of cholecystokinin B receptors in monkey brain. Brain Res 738: 313–318.
Morgan JI, Curran T (1995). Proto-oncogenes: beyond second messengers. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York. pp 631–642.
Pavlasevic S, Bednar I, Qureshi GA, Södersten P (1993). Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. NeuroReport 5: 225–228.
Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates 3th edn. Academic Press: New York.
Rehfeld JF (2000). Cholecystokinin and panic disorder—three unsettled questions. Reg Peptides 93: 79–83.
Rosen A, Brodin K, Eneroth P, Brodin E (1992). Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the periaqueductal grey and limbic regions of rat brain. Acta Physiol Scand 148: 341–348.
Russo AS, Guimarães FS, De Aguiar JC, Graeff FG (1993). Role of benzodiazepine receptors located in the dorsal periaqueductal grey of rats in anxiety. Psychopharmacology 110: 198–202.
Sewards TV, Sewards MA (2002). Fear and power-dominance motivation neural representation and pathways mediating sensory and mnemonic inputs and outputs to premotor structures. Neurosci Biobehav Rev 26: 553–579.
Shipley MT, Ennis M, Rizvi TA, Behbehani MM (1991). Topographical specificity of forebrain inputs to the midbrain periaqueductal gray: evidence for discrete longitudinally organized input columns. In: Depaulis A, Bandler R (eds). The Midbrain Periaqueductal Gray Matter: Functional, Anatomical and Neurochemical Organization. Plenum Press: New York. pp 417–448.
Silveira M.CL, Graeff FG, Sandner G (1994). Regional distribution of Fos-like immunoreactivity in the rat brain after exposure to fear-inducing stimuli. Braz J Med Biol Res 27: 1077–1081.
Singewald N, Sharp T (2000). Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience 98: 759–770.
Suh HW, Kim YH, Choi YS, Song DK (1995). Involvement of different subtypes of cholecystokinin receptors in opióide antinociception in the mouse. Peptides 16: 229–234.
Suh HW, Song DK, Kwon SH, Kim KW, Min BH, Kim YH (1996). Involvement of supraspinal and spinal CCK receptors in the modulation of antinociception induced by cold water swimming stress in the mouse. Neuropeptides 30: 379–384.
Treit D, Menard J, Royan C (1993). Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44: 463–469.
Wang H, Zhu YZ, Farrok JM, Moochhala S, Teo AL, Lee LKH et al (2003). Genetic variations in CCK2 receptor in PVG Hooded and Sprague–Dawley rats and its mRNA expression on cat exposure. Behav Neurosci 117: 385–390.
Acknowledgements
We thank JC de Aguiar and ET Gomes for the excellent technical support. Research supported by grants from FAPESP (98/10639-7, 02/13197-2), CAPES, and CNPq.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Netto, C., Guimarães, F. Anxiogenic Effect of Cholecystokinin in the Dorsal Periaqueductal Gray. Neuropsychopharmacol 29, 101–107 (2004). https://doi.org/10.1038/sj.npp.1300334
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.npp.1300334
Keywords
This article is cited by
-
The Periaqueductal Gray and Its Extended Participation in Drug Addiction Phenomena
Neuroscience Bulletin (2021)
-
Cholecystokinin Exerts an Effect via the Endocannabinoid System to Inhibit GABAergic Transmission in Midbrain Periaqueductal Gray
Neuropsychopharmacology (2011)
-
CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies
Amino Acids (2006)
-
The ascent of mouse: advances in modelling human depression and anxiety
Nature Reviews Drug Discovery (2005)